close read more

key Figures

22,500 employees

98% of Servier brand-name medicines

active ingredients are synthesized in France.

150 countries

in which the Group’s medicines are distributed

4 therapeutic areas

oncology, cardiometabolism, neuroscience and immuno-inflammation

42 projects

in clinical development, including 18 new molecular entities (October 2021).

A strong international presence

96% of Group revenue (from brand-name medicines) generated outside France.

16 chemical and pharmaceutical production sites

15 International Centers for Therapeutic Research

and 5 R&D centers (2 in France, 1 in Denmark, 1 in Hungary and 1 in the US).

€4.7 billion euros in revenue

comprising €3.3 billion for brand-name medicines and €1.4 billion for generic medicines.

23% of revenue from brand-name medicines invested in R&D

in 2019/2020

31st largest pharmaceutical Group worldwide

and 2nd largest pharmaceutical Group in France[1].

A leader position in cardiology in France

4th leading pharmaceutical Group worldwide[1].

Participation reached 36% of the trade balance surplus in France

in pharmaceuticals and fine chemicals (brand-name medicines), amounting to €1.6 billion.

Key figures as of September 30th, 2020

[1] Source: IQVA, Analytics Link – MAT Q2 2021